Benefits of integrating targeted next-generation sequencing (NGS) panels into molecular diagnostics of solid tumors

Variant detection of multiple genes from a single tumor sample requires high-throughput molecular testing. To meet this demand, targeted next-generation sequencing (NGS) panels are useful in clinical settings for accurate tumor profiling and the identification of essential molecular aberrations for personalized therapies. By focusing only on a subset of genes, targeted NGS is not only a cost-effective solution, but can rapidly deliver insights into a tumor molecular profile.

 

To address this challenge, a clinical research team led by Dr. Michela Bulfoni at the Istituto di Anatomia Patologica designed custom NGS panels, named “Glioma” and “Routine Diagnostics”, targeting single nucleotide variations, insertions/deletions, fusions, and copy number variations of tumor-associated essential genes.

 

In this webinar, attendees will: